Stay updated with breaking news from Demonstrating Potential. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
01.03.2023 - - Achieved $31.3 Million in Net Revenue from Sales of COSELA (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million - - Announced Top Line Results from Pivotal Phase 3 ...
- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) - -...
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index